强柱清感方辅助治疗成人重症流感的疗效与安全性评价:随机平行安慰剂对照双盲多中心试验的研究方案
本研究为随机、安慰剂对照、双盲、多中心试验,计划纳入228例成人重症流感患者,按1:1比例随机分配接受强柱清感方或安慰剂治疗7天,随访观察21天。主要结局为随机分组后7天内达到七分类序贯量表≤3分或国家早期预警评分2≤2分的临床改善比例。该研究旨在评估强柱清感方作为辅助治疗的疗效与安全性。
要点
- 强柱清感方辅助治疗成人重症流感:随机双盲安慰剂对照多中心试验方案。
- 计划纳入228例,1:1随机分配,干预7天,观察21天。
- 主要结局:7天内七分类序贯量表≤3分或NEWS2≤2分的临床改善比例。
核心结论
- 该研究旨在评估强柱清感方作为辅助治疗在成人重症流感患者中的疗效与安全性。
- 这是首个评价中药复方颗粒剂辅助治疗成人重症流感的随机、对照、平行、双盲临床试验。
研究设计与样本
- 研究方案依据SPIRIT指南和CONSORT中药复方扩展版制定。
- 采用随机、安慰剂对照、双盲、多中心试验设计。
- 计划纳入228例成人重症流感患者,按1:1比例随机分配至强柱清感方组或安慰剂组,治疗7天。
- 所有参与者随机分组前接受1天筛查,随机分组后干预7天,随后观察21天。
主要发现
- 主要结局为随机分组后7天内临床改善的比例,临床改善定义为七分类序贯量表评分≤3分或国家早期预警评分2(NEWS2)≤2分。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Influenza can fall into three categories according to severity: mild influenza, severe influenza, and critical influenza. Severe influenza can result in critical illness and sometimes death particularly in patients with comorbidities, advanced age, or pregnancy. Neuraminidase inhibitors (NAIs) are the only antiviral drugs in widespread use for influenza. However, the effectiveness of NAIs against severe influenza is uncertain. New effective drugs or regimens are therefore urgently needed. Qiangzhu-qinggan (QZQG) formula has been found to be effective against influenza virus infection during long-term application in China, which lacks support of evidence-based clinical trial till now. This study is designed to assess the efficacy and safety of QZQG formula as an adjuvant therapy in adult patients with severe influenza. METHODS: This protocol is drawn up in accordance with the SPIRIT guidelines and CONSORT Extension for Chinese herbal medicine formulas. This is a randomized, placebo-controlled, double-blind, multicenter trial. Two hundred twenty-eight adults with severe influenza are randomly assigned in a 1:1 ratio to QZQG or placebo for 7 days. All participants need to receive 1 day of screening before randomization, 7 days of intervention, and 21 days of observation after randomization. The primary outcome is the proportion of clinical improvement, defined as the proportion of patients who met the criteria of 3 points or less in the seven-category ordinal scale or 2 points or less in National Early Warning Score 2 within 7 days after randomization. DISCUSSION: This is the first randomized, controlled, parallel, double-blind clinical trial to evaluate the efficacy and safety of traditional Chinese herbal formula granules as an adjuvant therapy in adult patients with severe influenza. This study aims to redefine the value of traditional Chinese herbal medicines in the treatment of virus-related respiratory infectious diseases and serves as an example of evidence-based clinical trials of other Chinese herbal medicines.
引用
- Qiu L, Wu XW, Zhang SY, et al. Evaluation of efficacy and safety of Qiangzhu-qinggan formula as an adjunctive therapy in adult patients with severe influenza: study protocol for a randomized parallel placebo-controlled double-blind multicenter trial. Trials. 2021. PMID: 34961550. doi:10.1186/s13063-021-05929-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。